Risankizumab Maintenance Therapy Is Effective in Patients Achieving CDAI Clinical Response With Induction Therapy: Post Hoc Analysis From FORTIFY

Authors

• Marla Dubinsky, Icahn School of Medicine at Mount Sinai, New York, NY
• David Rubin, The University of Chicago Medicine, Chicago, IL
• Florian Rieder, The University of Chicago Medicine, Chicago, IL
• J. Casey Chapman, LSU Health Sciences Center - New Orleans
• Alexandra Song, AbbVie, Mettawa, IL
• Kristina Kligys, AbbVie, Mettawa, IL
• Xiaomei Liao, AbbVie, Mettawa, IL
• Javier Zambrano, AbbVie, Mettawa, IL
• Stephen Hanauer, Northwestern University, Chicago, IL

Document Type

Conference Proceeding

Publication Date

1-1-2022

Publication Title

American Journal of Gastroenterology

Abstract

2022 Advances in Inflammatory Bowel Diseases Annual Meeting, December 5-7, 2022 Orlando, Florida

First Page

S23

Last Page

S23

Comments

Abstract S87

Rights

© 2022 by The American College of Gastroenterology

Recommended Citation

Dubinsky, Marla; Rubin, David; Rieder, Florian; Chapman, J. Casey; Song, Alexandra; Kligys, Kristina; Liao, Xiaomei; Zambrano, Javier; and Hanauer, Stephen, "Risankizumab Maintenance Therapy Is Effective in Patients Achieving CDAI Clinical Response With Induction Therapy: Post Hoc Analysis From FORTIFY" (2022). School of Medicine Faculty Publications. 4724.
https://digitalscholar.lsuhsc.edu/som_facpubs/4724
10.14309/01.ajg.0000897856.16758.ae